NovAccess Global Inc. announced the signing of a Letter of Intent (LOI) and formation of a partnership with BCN Biosciences to expand its immunotherapy platform. Utilizing BCN's small molecule drug BCN057, developed with support from the National Institutes of Health and in collaboration with the University of California Los Angeles (UCLA), NovAccess Global has begun the development of a fourth generation of its novel brain tumor immunotherapy TLR-AD1, targeting glioblastoma. Awarded Orphan Drug Status by the U.S. Food and Drug Administration in 2022, TLR-AD1improves the ability of specialized blood cells, known as Dendritic Cells (DCs), to recognize tumors.

These specialized blood cells then provide a 'zip code' to the immune system improving its ability to seek out and destroy tumor cells in the body. While TLR-AD1 is the most advanced technology to enhance DC immunotherapy, a combination therapy leveraging BCN057 could further enhance DC tumor recognition as well as increase DC yield from patients' blood. The partnership between NovAccess Global and BCN provides a unique opportunity to further develop BCN057 in combination with TLR-AD1 to benefit patients with CNS cancer and potentially other cancer tumor types.

Based in Pasadena, CA and founded more than ten years ago, BCN Biosciences is a privately held oncology-focused drug development company leveraging long-term partnerships with NIH, Kansas University Medical Center, and UCLA. BCN has a portfolio of drug assets focusing on novel cancer targets and therapies that affect how cancer cells evolve the body's immune system. BCN is currently developing two classes of novel small molecule drugs that target the RAS signaling pathway, a key molecular switch in the development of malignancies, and improve patient response to current classes of immune oncology therapy.

The partnership with BCN will further strengthen the IP portfolio supporting NovAccess Global's 4th generation of TLR-AD1. This partnership will increase opportunities for third-party licensing of NovAccess Global's drug platform to pharmaceutical companies active in developing new classes of therapies to compete in the global immune oncology market which exceeds more than $100 billion a year. NovAccess Global plans to enhance TLR-AD1with its artificial intelligence (AI) driven Precision Medicine Division.

Through this division, NovAccess intends to develop a comprehensive collection of personalized therapeutics and treatment protocols leveraging advances in bioinformatics, computational science, and molecular medicine. Clinical insights from the Precision Medicine Division will help to determine which drug variation based on the TLR-AD1 platform is most appropriate for patients to illicit the strongest and most durable immune response to their individual tumor type.